Fas Signaling is focused on the signaling mechanisms and biology of the prototypic death receptor Fas, also called CD95 or APO-1. The chapters of this book cover, besides the well recognized apoptosis-related functions of Fas, its emerging role as a proinflammatory cytokine and as an inducer of alternative forms of cell death. Fas Signaling aims to provide the reader with an up-to-date survey of the various aspects of Fas biology and the open questions of the field are addressed. This title is intended for Ph.D and post-doctoral students starting to work in the field, but is also useful for everyone with an interest in the biology of this exciting molecule.

Recent advances have carried hepatology to new frontiers. The increasing frequency with which steatotic and cirrhotic livers undergo surgery obliges liver surgeons and hepatologists to understand the molecular mechanisms at play in these situations. Comprehension of the signaling pathways participating in liver regeneration, hepatocellular apoptosis and ischemia/reperfusion injury is essential. This book serves as a source of information to facilitate the reading of the literature and the planning of trials. Translational medicine implies knowledge of the molecular targets of novel therapeutic strategies. It is our goal to stimulate more research that can lead to more exchanges between the laboratory, the clinical ward and the operating room.

Completely revised and expanded, this second edition of The Cytokine FactsBook is the most up-to-date reference manual available for all current well-characterized interleukins, cytokines, and their receptors. An additional 52 cytokines are included, doubling the number of entries from the previous edition. The key properties of each cytokine are described and presented in a very accessible format with diagrams for each of the receptors. The Cytokine FactsBook includes free online access to the regularly updated Cytokine Webfacts. Cytokine Webfacts is a web-based comprehensive compendium of facts about cytokines and their receptors that includes a variety of data representations, such as text, signal pathway diagrams and 3D images. This exciting resource is integrated into other databases via hypertext links to provide a unique network, and contains a web-enabled version of RasMol for viewing structures.

Signaling Pathways in Liver Diseases, Third Edition again provides hepatologists and hepatology researchers with an expert overview of the complex and novel cellular/extracellular signaling pathways in the liver, and their role in liver diseases. The last few years have seen a great number of developments in this field, which in turn have led to new opportunities for innovative treatments; however, the intricacy of these pathways and their interactions continue to provide a real challenge for clinicians. This outstanding book compiles the emerging knowledge into a single expert resource, cataloguing and organizing it into an accessible and understandable format. With increased focus on the comprehension of cellular mechanisms involved in steatohepatitis, cirrhosis, and liver tumors, which has led to changes in the management of these diseases, this new edition also sees the introduction of exciting new chapters on key emerging areas such as: Autophagy Notch Pathway P13K/PTEN Signaling in Liver Diseases Sirtuins Hepcidin and Iron Epigenetic Regulation of Hepatic Stellate Cells and Liver Fibrosis Oxidative Stress and Signaling in the Liver. Professors Dufour and Clavien have assembled an all-star cast of chapter authors, each of whom has provided clear and appropriate illustrations to reinforce the text, with a key points box offering a concise and handy summary. Self-assessment questions and answers allow the reader to test their own knowledge. Signaling Pathways in Liver Disease, Third Edition is the perfect educational and reference tool to bridge the information exchange between the laboratory, the clinical ward, and the operating room, and an essential tool for the modern-day hepatologist.

This book is devoted to innovative medicine, comprising the proceedings of the Uehara Memorial Foundation Symposium 2014. It remains extremely rare for the findings of basic research to be developed into clinical applications, and it takes a long time for the process to be achieved. The task of advancing the development of basic research into clinical reality lies with translational science, yet the field seems to struggle to find a way to move forward. To create innovative medical technology, many steps need to be taken: development and analysis of optimal animal models of human diseases, elucidation of genomic and epidemiological data, and establishment of “proof of concept”. There is also considerable demand for progress in drug research, new surgical procedures, and new clinical devices and equipment. While the original research target may be rare diseases, it is also important to apply those findings more broadly to common diseases. The book covers a wide range of topics and is organized into three complementary parts. The first part is basic research for innovative medicine, the second is translational research for innovative medicine, and the third is new technology for innovative medicine. This book helps to understand innovative medicine and to make progress in its realization.

This thoroughly revised second edition is an up-to-date overview of the new advances in the knowledge of the basic science in sarcoma and osteosarcoma. It features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, this essential volume also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists.